Report cover image

Plasma Therapy

Published May 01, 2026
Length 275 Pages
SKU # GJOB21161383

Description

REPORT HIGHLIGHTS

Global Plasma Therapy Market to Reach US$1.1 Billion by 2032

The global market for Plasma Therapy estimated at US$646.0 Million in the year 2025, is expected to reach US$1.1 Billion by 2032, growing at a CAGR of 7.3% over the analysis period 2025-2032. Pure PRP Type, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$439.4 Million by the end of the analysis period. Growth in the Leukocyte-Rich PRP Type segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$191.1 Million While China is Forecast to Grow at 7.1% CAGR

The Plasma Therapy market in the U.S. is estimated at US$191.1 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$187.5 Million by the year 2032 trailing a CAGR of 7.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Plasma Therapy Market - Key Trends and Drivers Summarized

Healing from Within: The Promises and Processes of Plasma Therapy

Plasma therapy, also known as platelet-rich plasma (PRP) therapy, is a medical treatment that utilizes the patient’s own blood to accelerate healing in various parts of the body. The process begins with a blood draw, from which the plasma, rich in platelets and growth factors, is isolated through centrifugation. This concentrated plasma is then injected into the injured or affected area. Platelets play a crucial role in clotting and tissue repair, and the growth factors they release can stimulate cell proliferation, tissue regeneration, and healing. This therapy is increasingly popular in fields like orthopedics, sports medicine, and dermatology for its potential to enhance recovery and reduce inflammation.

How Is Plasma Therapy Applied in Different Medical Fields?

Plasma therapy is utilized across a range of medical fields due to its regenerative properties. In orthopedics and sports medicine, PRP injections are used to treat chronic tendon injuries, such as tennis elbow and Achilles tendinitis, as well as acute injuries like ligament sprains and muscle strains. These injections can also aid in the recovery from surgeries, enhancing the healing process and reducing downtime. In dermatology, plasma therapy is employed for facial rejuvenation, reducing wrinkles, and improving skin texture through procedures commonly known as the “vampire facial.” Additionally, PRP is used in hair restoration treatments, promoting hair growth in patients experiencing hair loss. The versatility of plasma therapy makes it a valuable tool in both restorative and aesthetic medicine, offering patients a natural and effective treatment option.

What Are the Current Trends in Plasma Therapy Research and Applications?

The field of plasma therapy is continuously evolving, driven by ongoing research and clinical advancements. One significant trend is the increasing use of PRP in combination with other treatments, such as stem cell therapy and microneedling, to enhance therapeutic outcomes. Researchers are also exploring the efficacy of plasma therapy in new areas, such as treating degenerative joint diseases like osteoarthritis and promoting wound healing in diabetic patients. Advances in PRP preparation techniques are improving the consistency and potency of the treatments, making them more reliable and effective. Additionally, there is a growing emphasis on understanding the specific components of PRP and how different concentrations of platelets and growth factors can be optimized for various conditions. These trends reflect the dynamic nature of plasma therapy research, aiming to broaden its applications and improve patient outcomes.

What Factors Are Driving the Growth in the Plasma Therapy Market?

The growth in the plasma therapy market is driven by several factors, reflecting the increasing demand for innovative and effective medical treatments. Rising awareness of the benefits of PRP therapy, coupled with its minimally invasive nature and lower risk of side effects, is attracting more patients and healthcare providers. Technological advancements in PRP preparation and delivery methods are enhancing the efficacy and reliability of treatments, further boosting their popularity. The expanding applications of plasma therapy in diverse medical fields, including orthopedics, dermatology, and hair restoration, are contributing to market growth. Additionally, the growing trend towards regenerative medicine and personalized treatments is driving interest in PRP as a natural and patient-specific therapy. Increased healthcare spending and the expansion of medical infrastructure in developing regions are also supporting market growth, making these advanced treatments more accessible. These factors collectively ensure robust growth in the plasma therapy market, highlighting its significant potential in modern healthcare.

SCOPE OF STUDY:

The report analyzes the Plasma Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type, Leukocyte-Rich Fibrin Type); Source (Autologous Source, Allogenic Source); Application (Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application, Other Applications); End-Use (Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -
  • Active Sports Medicine
  • Alkahest, Inc.
  • Bio Products Laboratory Ltd.
  • Biolife Plasma Services
  • CSL Ltd.
  • Excelsior Orthopaedics
  • Glofinn Oy
  • Juventix
  • Octapharma AG
  • Origin, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

275 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
Plasma Therapy – Global Key Competitors Percentage Market Share in 2026 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Chronic Diseases Propels Market Growth
Advances in Plasma-Derived Therapies Drives Adoption
Rising Demand for Immunoglobulin Therapies Expands Market Opportunities
Growth in Geriatric Population Strengthens Business Case for Plasma Therapy
Development of Novel Plasma Treatments Spurs Market Expansion
Expansion of Blood Plasma Donation Centers Generates Demand
Increasing Focus on Personalized Medicine Accelerates Market Growth
Enhanced Safety and Efficacy of Modern Plasma Therapies Sustains Market Demand
Rising Investments in Plasma Research and Development Expands Addressable Market
Technological Innovations in Plasma Fractionation Strengthens Market Position
Development of Recombinant Plasma Products Generates Market Opportunities
Growth in Hemophilia and Coagulation Disorder Treatments Propels Market Growth
Increasing Demand for Convalescent Plasma Therapy Sustains Market Expansion
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Plasma Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 2: World Historic Review for Plasma Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 3: World 13-Year Perspective for Plasma Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
TABLE 4: World Plasma Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
TABLE 5: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 6: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 7: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 8: World Recent Past, Current & Future Analysis for Pure PRP Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 9: World Historic Review for Pure PRP Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 10: World 13-Year Perspective for Pure PRP Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 11: World Recent Past, Current & Future Analysis for Leukocyte-Rich PRP Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 12: World Historic Review for Leukocyte-Rich PRP Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 13: World 13-Year Perspective for Leukocyte-Rich PRP Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 14: World Recent Past, Current & Future Analysis for Pure Platelet-Rich Fibrin Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 15: World Historic Review for Pure Platelet-Rich Fibrin Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 16: World 13-Year Perspective for Pure Platelet-Rich Fibrin Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 17: World Recent Past, Current & Future Analysis for Leukocyte-Rich Fibrin Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 18: World Historic Review for Leukocyte-Rich Fibrin Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 19: World 13-Year Perspective for Leukocyte-Rich Fibrin Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 20: World Recent Past, Current & Future Analysis for Autologous Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 21: World Historic Review for Autologous Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 22: World 13-Year Perspective for Autologous Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 23: World Recent Past, Current & Future Analysis for Allogenic Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 24: World Historic Review for Allogenic Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 25: World 13-Year Perspective for Allogenic Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 26: World Recent Past, Current & Future Analysis for Wound Care Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 27: World Historic Review for Wound Care Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 28: World 13-Year Perspective for Wound Care Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 29: World Recent Past, Current & Future Analysis for Dermatology & Aesthetics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 30: World Historic Review for Dermatology & Aesthetics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 31: World 13-Year Perspective for Dermatology & Aesthetics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 32: World Recent Past, Current & Future Analysis for Orthopedics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 33: World Historic Review for Orthopedics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 34: World 13-Year Perspective for Orthopedics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 35: World Recent Past, Current & Future Analysis for Hospitals & ASCs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 36: World Historic Review for Hospitals & ASCs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 37: World 13-Year Perspective for Hospitals & ASCs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 38: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 39: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 40: World 13-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 41: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 42: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 43: World 13-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 46: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
TABLE 47: USA Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 48: USA Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 49: USA 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 50: USA Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 51: USA Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 52: USA 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 53: USA Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 54: USA Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 55: USA 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 56: USA Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 57: USA Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 58: USA 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
CANADA
TABLE 59: Canada Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 60: Canada Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 61: Canada 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 62: Canada Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 63: Canada Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 64: Canada 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 65: Canada Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 66: Canada Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 67: Canada 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 68: Canada Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 69: Canada Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 70: Canada 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
JAPAN
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
TABLE 71: Japan Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 72: Japan Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 73: Japan 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 74: Japan Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 75: Japan Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 76: Japan 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 77: Japan Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 78: Japan Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 79: Japan 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 80: Japan Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 81: Japan Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 82: Japan 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
CHINA
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
TABLE 83: China Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 84: China Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 85: China 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 86: China Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 87: China Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 88: China 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 89: China Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 90: China Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 91: China 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 92: China Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 93: China Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 94: China 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
EUROPE
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
TABLE 95: Europe Recent Past, Current & Future Analysis for Plasma Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
TABLE 96: Europe Historic Review for Plasma Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 97: Europe 13-Year Perspective for Plasma Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
TABLE 98: Europe Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 99: Europe Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 100: Europe 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 101: Europe Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 102: Europe Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 103: Europe 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 104: Europe Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 105: Europe Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 106: Europe 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 107: Europe Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 108: Europe Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 109: Europe 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
FRANCE
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
TABLE 110: France Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 111: France Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 112: France 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 113: France Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 114: France Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 115: France 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 116: France Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 117: France Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 118: France 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 119: France Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 120: France Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 121: France 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
GERMANY
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
TABLE 122: Germany Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 123: Germany Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 124: Germany 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 125: Germany Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 126: Germany Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 127: Germany 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 128: Germany Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 129: Germany Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 130: Germany 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 131: Germany Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 132: Germany Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 133: Germany 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
ITALY
TABLE 134: Italy Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 135: Italy Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 136: Italy 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 137: Italy Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 138: Italy Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 139: Italy 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 140: Italy Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 141: Italy Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 142: Italy 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 143: Italy Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 144: Italy Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 145: Italy 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
UNITED KINGDOM
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
TABLE 146: UK Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 147: UK Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 148: UK 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 149: UK Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 150: UK Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 151: UK 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 152: UK Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 153: UK Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 154: UK 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 155: UK Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 156: UK Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 157: UK 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
REST OF EUROPE
TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 159: Rest of Europe Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 160: Rest of Europe 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 162: Rest of Europe Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 163: Rest of Europe 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 165: Rest of Europe Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 166: Rest of Europe 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 168: Rest of Europe Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 169: Rest of Europe 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
ASIA-PACIFIC
Plasma Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 171: Asia-Pacific Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 172: Asia-Pacific 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 174: Asia-Pacific Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 175: Asia-Pacific 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 177: Asia-Pacific Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 178: Asia-Pacific 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 180: Asia-Pacific Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 181: Asia-Pacific 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
REST OF WORLD
TABLE 182: Rest of World Recent Past, Current & Future Analysis for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 183: Rest of World Historic Review for Plasma Therapy by Type - Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 184: Rest of World 13-Year Perspective for Plasma Therapy by Type - Percentage Breakdown of Value Sales for Pure PRP Type, Leukocyte-Rich PRP Type, Pure Platelet-Rich Fibrin Type and Leukocyte-Rich Fibrin Type for the Years 2020, 2026 & 2032
TABLE 185: Rest of World Recent Past, Current & Future Analysis for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 186: Rest of World Historic Review for Plasma Therapy by Application - Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 187: Rest of World 13-Year Perspective for Plasma Therapy by Application - Percentage Breakdown of Value Sales for Wound Care Application, Dermatology & Aesthetics Application, Orthopedics Application and Other Applications for the Years 2020, 2026 & 2032
TABLE 188: Rest of World Recent Past, Current & Future Analysis for Plasma Therapy by Source - Autologous Source and Allogenic Source - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 189: Rest of World Historic Review for Plasma Therapy by Source - Autologous Source and Allogenic Source Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 190: Rest of World 13-Year Perspective for Plasma Therapy by Source - Percentage Breakdown of Value Sales for Autologous Source and Allogenic Source for the Years 2020, 2026 & 2032
TABLE 191: Rest of World Recent Past, Current & Future Analysis for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
TABLE 192: Rest of World Historic Review for Plasma Therapy by End-Use - Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
TABLE 193: Rest of World 13-Year Perspective for Plasma Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & ASCs End-Use, Specialty Clinics End-Use, Research Institutes End-Use and Other End-Uses for the Years 2020, 2026 & 2032
IV. COMPETITION
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.